FDA label b75779c4-620c-4247-98c6-f0987d364b76
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- b0ed0215-ba60-45c6-8b1e-3d527cdce9ce
- SPL ID
- b75779c4-620c-4247-98c6-f0987d364b76
- Version
- 14
- Effective date
- 2022-08-24
- Source export date
- 2026-11-13
- Source partition
- 4
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:58:32
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | b75779c4-620c-4247-98c6-f0987d364b76 | id | |
| spl set id | b0ed0215-ba60-45c6-8b1e-3d527cdce9ce | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Colitis: Clindamycin can cause severe colitis, which may result in death. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of clindamycin. Clindamycin Phosphate and Tretinoin Gel should be discontinued if significant diarrhea occurs. ( 5.1 ) Ultraviolet Light and Environmental Exposure: Avoid exposure to sunlight, sunlamps, and weather extremes. Wear sunscreen daily. ( 5.2 ) 5.1 Colitis Systemic absorption of clindamycin has been demonstrated following topical use. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical clindamycin. If significant diarrhea occurs, Clindamycin Phosphate and Tretinoin Gel should be discontinued. Severe colitis has occurred following oral or parenteral administration of clindamycin with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death. Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically. 5.2 Ultraviolet Light and Environmental Exposure Exposure to sunlight, including sunlamps, should be avoided during the use of Clindamycin Phosphate and Tretinoin Gel. Patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight as a result of the use of tretinoin. Patients who may be required to have considerable sun exposure due to occupation and those with inherent sensitivity to the sun should exercise particular caution. Daily use of sunscreen products and protective apparel (e.g., a hat) are recommended. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with Clindamycin Phosphate and Tretinoin Gel.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS Observed local treatment-related adverse reactions (≥ 1%) in clinical trials with Clindamycin Phosphate and Tretinoin Gel were application site reactions, including dryness, irritation, exfoliation, erythema, pruritus, and dermatitis. Sunburn was also reported. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aqua Pharmaceuticals, at 1-866-665-2782 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Adverse Reactions in Clinical Trials Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety data reflect exposure to Clindamycin Phosphate and Tretinoin Gel in 1,104 subjects with acne vulgaris. Subjects were 12 years and older and were treated once daily in the evening for 12 weeks. Adverse reactions that were reported in ≥1% of subjects treated with Clindamycin Phosphate and Tretinoin Gel are presented in Table 1. Table 1. Treatment-Related Adverse Reactions Reported by ≥1% of Subjects Clindamycin Phosphate and Tretinoin Gel N = 1,104 n (%) Clindamycin Gel N = 1,091 n (%) Tretinoin Gel N = 1,084 n (%0) Vehicle Gel N = 552 n (%) Patients with at least one adverse reaction 140 (13) 38 (3) 141 (13) 17 (3) Application site dryness 64 (6) 12 (1) 62 (6) 3 (1) Application site irritation 50 (5) 4 (<1) 57 (5) 5 (<1) Application site exfoliation 50 (5) 2 (<1) 56 (5) 2 (<1) Application site erythema 40 (4) 6 (1) 39 (4) 3 (1) Application site pruritus 26 (2) 7 (1) 23 (2) 6 (1) Sunburn 11 (1) 6 (1) 7 (1) 3 (1) Application site dermatitis 6 (1) 0 (0) 8 (1) 1 (<1) Local skin reactions actively assessed at baseline and end of treatment with a score >0 are presented in Table 2. Table 2. Local Skin Reactions in Subjects Treated With Clindamycin Phosphate and Tretinoin Gel Clindamycin Phosphate and Tretinoin Gel Vehicle Gel Local Reaction Baseline N=476 (%) End of Treatment N= 409 (%) Baseline N=219 (%) End of Treatment N=209 (%) Erythema 24% 21% 31% 35% Scaling 8% 19% 14% 12% Dryness 11% 22% 18% 13% Burning 8% 13% 8% 4% Itching 17% 15% 22% 14% During the 12 weeks of treatment, each local skin reaction peaked at Week 2 and gradually reduced thereafter.
adverse reactions table
<table><col/><col/><col/><col/><col/><tbody><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> </td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"><paragraph><content styleCode="bold">Clindamycin Phosphate and Tretinoin Gel</content></paragraph><paragraph><content styleCode="bold">N = 1,104 n (%)</content></paragraph></td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"><paragraph><content styleCode="bold">Clindamycin Gel</content></paragraph><paragraph><content styleCode="bold">N = 1,091 n (%)</content></paragraph></td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"><paragraph><content styleCode="bold">Tretinoin Gel</content></paragraph><paragraph><content styleCode="bold">N = 1,084 n (%0)</content></paragraph></td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"><paragraph><content styleCode="bold">Vehicle Gel</content></paragraph><paragraph><content styleCode="bold">N = 552 n (%) </content></paragraph></td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Patients with at least one adverse reaction</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 140 (13)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 38 (3)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 141 (13)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 17 (3)</td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Application site dryness</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 64 (6)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 12 (1)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 62 (6)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 3 (1)</td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Application site irritation</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 50 (5)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 4 (<1)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 57 (5)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 5 (<1)</td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Application site exfoliation</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 50 (5)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 2 (<1)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 56 (5)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule">2 (<1)</td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule">Application site erythema </td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 40 (4)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 6 (1)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule">39 (4)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule">3 (1)</td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Application site pruritus</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule">26 (2)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule">7 (1)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 23 (2)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule">6 (1)</td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule">Sunburn </td><td align="center" styleCode=" Botrule Toprule Lrule Rrule">11 (1)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 6 (1)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 7 (1)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule">3 (1) </td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Application site dermatitis</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 6 (1)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 0 (0)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8 (1)</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 1 (<1)</td></tr></tbody></table>
adverse reactions table
<table width="565px"><col/><col/><col/><col/><col/><tbody><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> </td><td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"><paragraph> Clindamycin Phosphate</paragraph><paragraph>and Tretinoin Gel </paragraph></td><td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule"> Vehicle Gel</td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule">Local Reaction </td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"><paragraph> Baseline</paragraph><paragraph>N=476</paragraph><paragraph>(%)</paragraph></td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"><paragraph> End of Treatment</paragraph><paragraph>N= 409</paragraph><paragraph>(%)</paragraph></td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"><paragraph>Baseline</paragraph><paragraph>N=219</paragraph><paragraph>(%)</paragraph></td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"><paragraph> End of Treatment</paragraph><paragraph>N=209</paragraph><paragraph>(%)</paragraph></td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Erythema</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 24%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 21%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 31%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 35%</td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Scaling</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 19%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 12%</td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Dryness</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 11%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 22%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 18%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 13%</td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Burning</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 13%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 8%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 4%</td></tr><tr><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> Itching</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 17%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 15%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 22%</td><td align="center" styleCode=" Botrule Toprule Lrule Rrule"> 14%</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.